SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination was written by Li, Pengfei;Wang, Yining;Lavrijsen, Marla;Lamers, Mart M.;de Vries, Annemarie C.;Rottier, Robbert J.;Bruno, Marco J.;Peppelenbosch, Maikel P.;Haagmans, Bart L.;Pan, Qiuwei. And the article was included in Cell Research in 2022.Quality Control of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate The following contents are mentioned in the article:
A review. Since the first outbreak in late 2019, the RNA genome of SARSCoV-2 has been undergoing constant evolution. This is largely attributed to the viral polymerase that is intrinsically error prone and the selection pressures exerted by the host immune system. Several variants of concern harboring multiple mutations in the spike protein have emerged in the past year. The currently fast-spreading Omicron variant contains many more mutations compared with the previous variants, and most of these mutations are located around the receptor binding domain of the spike protein. This would dramatically, although not completely, compromise the efficacy of the existing COVID-19 vaccines. In summary, this study has demonstrated that molnupiravir and nirmatrelvir potently inhibited the infection of SARS-CoV-2 Omicron variant. Combination of molnupiravir and nirmatrelvir exerted synergistic antiviral activity. Of note, there are some subtle differences regarding the patterns of antiviral response among WT, Omicron and Delta variants, as well as between cell line and organoid models. Nevertheless, our findings support the use of molnupiravir and nirmatrelvir for treating Omicron-infected patients. We further call the initiation of clin. studies to evaluate the combination of molnupiravir and nirmatrelvir for treating COVID-19. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Quality Control of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran and dihydrofuran form the basic structural unit of many naturally occurring scaffolds like gambieric acid A and ciguatoxin, goniocin, and some biologically active molecules. THF can also be synthesized by catalytic hydrogenation of furan. This allows certain sugars to be converted to THF via acid-catalyzed digestion to furfural and decarbonylation to furan, although this method is not widely practiced. THF is thus derivable from renewable resources.Quality Control of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem